Samuel F. Gerard

Samuel F. Gerard

Auto-generated profile, based on publicly available information

Samuel F. Gerard

Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2020 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
TNTao Ni
Tao Ni
SGSamuel Gerard
Samuel Gerard
GZGongpu Zhao
Gongpu Zhao
KDKyle Dent
Kyle Dent
JNJiying Ning
Jiying Ning
PZPeijun Zhang
Peijun Zhang

27 May 2019 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
TRThomas. A. Rawlinson
Thomas. A. Rawlinson
NBNatalie M. Barber
Natalie M. Barber
FMFranziska Mohring
Franziska Mohring
JCJee Sun Cho
Jee Sun Cho
VKVarakorn Kosaisavee
Varakorn Kosaisavee
SDSimon Draper
Simon Draper
The most widespread form of malaria is caused by Plasmodium vivax. To replicate, this parasite must invade immature red blood cells through a process requiring interaction of the P. vivax Duffy binding protein (PvDBP) with its human receptor, the Duffy antigen receptor for chemokines. Naturally acquired antibodies that inhibit this interaction associate with clinical immunity, suggesting PvDBP as a leading candidate for inclusion in a vaccine to prevent malaria due to P. vivax. Here, we isolated a panel of monoclonal antibodies from human volunteers immunized in a clinical vaccine trial of PvDBP. We screened their ability to prevent PvDBP from binding to the Duffy antigen receptor for chemokines, and their capacity to block red blood cell invasion by a transgenic Plasmodium knowlesi parasite genetically modified to express PvDBP and to prevent reticulocyte invasion by multiple clinical isolates of P. vivax. This identified a broadly neutralizing human monoclonal antibody that inhibited invasion of all tested strains of P. vivax. Finally, we determined the structure of a complex of this antibody bound to PvDBP, indicating the molecular basis for inhibition. These findings will guide future vaccine design strategies and open up possibilities for testing the prophylactic use of such an antibody.

1 August 2020 in Molecular Cell
Verified
Journal Article
Open access
SGSamuel F. Gérard
Samuel F. Gérard
BHBelinda S. Hall
Belinda S. Hall
AZAfroditi M. Zaki
Afroditi M. Zaki
KCKatherine A. Corfield
Katherine A. Corfield
PMPeter U. Mayerhofer
Peter U. Mayerhofer
MHMatthew K. Higgins
Matthew K. Higgins
Protein secretion in eukaryotes and prokaryotes involves a universally conserved protein translocation channel formed by the Sec61 complex. Unrelated small-molecule natural products and synthetic compounds inhibit Sec61 with differential effects for different substrates or for Sec61 from different organisms, making this a promising target for therapeutic intervention. To understand the mode of inhibition and provide insight into the molecular mechanism of this dynamic translocon, we determined the structure of mammalian Sec61 inhibited by the Mycobacterium ulcerans exotoxin mycolactone via electron cryo-microscopy. Unexpectedly, the conformation of inhibited Sec61 is optimal for substrate engagement, with mycolactone wedging open the cytosolic side of the lateral gate. The inability of mycolactone-inhibited Sec61 to effectively transport substrate proteins implies that signal peptides and transmembrane domains pass through the site occupied by mycolactone. This provides a foundation for understanding the molecular mechanism of Sec61 inhibitors and reveals novel features of translocon function and dynamics.

1 July 2018 in Journal of Structural Biology
Verified
Journal Article
Closed access
ASAshwani Sharma
Ashwani Sharma
SGSamuel F. Gerard
Samuel F. Gerard
NONatacha Olieric
Natacha Olieric
MSMichel O. Steinmetz
Michel O. Steinmetz